A214390 Stock Overview
Manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Kyongbo Pharmaceutical Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,440.00 |
| 52 Week High | ₩10,950.00 |
| 52 Week Low | ₩6,060.00 |
| Beta | 1.17 |
| 11 Month Change | 0% |
| 3 Month Change | -2.75% |
| 1 Year Change | 2.90% |
| 33 Year Change | -44.06% |
| 5 Year Change | -24.31% |
| Change since IPO | -78.28% |
Recent News & Updates
Recent updates
Kyongbo Pharmaceutical (KRX:214390) Has A Somewhat Strained Balance Sheet
Mar 09
What Type Of Shareholders Own The Most Number of Kyongbo Pharmaceutical Co., Ltd (KRX:214390) Shares?
Feb 02Kyongbo Pharmaceutical Co., Ltd's (KRX:214390) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Jan 12Did You Miss Kyongbo Pharmaceutical's (KRX:214390) Impressive 107% Share Price Gain?
Dec 25Is Kyongbo Pharmaceutical (KRX:214390) A Risky Investment?
Dec 08
Does Kyongbo Pharmaceutical's (KRX:214390) Statutory Profit Adequately Reflect Its Underlying Profit?
Nov 18Shareholder Returns
| A214390 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 0% | -3.0% | -1.2% |
| 1Y | 2.9% | 25.6% | 4.8% |
Return vs Industry: A214390 underperformed the KR Pharmaceuticals industry which returned 7% over the past year.
Return vs Market: A214390 underperformed the KR Market which returned 6.5% over the past year.
Price Volatility
| A214390 volatility | |
|---|---|
| A214390 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.2% |
| 10% least volatile stocks in KR Market | 3.5% |
Stable Share Price: A214390 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine A214390's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Tae-Young Kim | www.kbpharma.co.kr |
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE.
Kyongbo Pharmaceutical Co., Ltd Fundamentals Summary
| A214390 fundamental statistics | |
|---|---|
| Market cap | ₩177.87b |
| Earnings (TTM) | ₩5.36b |
| Revenue (TTM) | ₩231.00b |
33.2x
P/E Ratio0.8x
P/S RatioIs A214390 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A214390 income statement (TTM) | |
|---|---|
| Revenue | ₩231.00b |
| Cost of Revenue | ₩160.68b |
| Gross Profit | ₩70.32b |
| Other Expenses | ₩64.96b |
| Earnings | ₩5.36b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 224.37 |
| Gross Margin | 30.44% |
| Net Profit Margin | 2.32% |
| Debt/Equity Ratio | 52.4% |
How did A214390 perform over the long term?
See historical performance and comparison